Wolters Kluwer Sentri7® Drug Diversion is a healthcare analytics and case-management solution that detects, investigates, documents, and reports potential medication diversion across the medication lifecycle using AI/ML-based anomaly detection and multi-source data integration.
Published May 16, 2026
Mainstream review platforms (G2, TrustRadius, Capterra, Gartner Peer Insights) did not surface readily accessible, product-specific review pages for Sentri7 Drug Diversion during this research run. In this category, buyers often rely on KLAS and peer references.
A Wolters Kluwer vendor announcement includes a named customer quote from a pharmacy leader at Mary Lanning Healthcare highlighting increased proactivity and continued support quality under the Sentri7 umbrella. Vendor-selected testimonials are inherently positive and not representative of the full customer base.
Most aligned with:
Get a comprehensive analysis of Wolters Kluwer Sentri7® Drug Diversion including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →Organizations that cannot reliably integrate the necessary data sources If an organization has only partial data (for example, ADC without time clocks or procedure context, or inconsistent waste documentation), the solution may generate noisy alerts and provide limited end-to-end traceability.
Procurement processes that require publicly available product-specific security attestations upfront If procurement requires publicly verifiable SOC 2 Type II or ISO 27001 statements for the specific SaaS module prior to engaging under NDA, this product may add procurement friction based on limited public documentation.
Buying processes that depend on abundant, readily accessible third-party reviews If a procurement process relies on a high volume of G2/TrustRadius-style reviews, the visible footprint for this module is thinner than many horizontal SaaS tools.
When primary needs are ADC operational issues rather than cross-system diversion analytics If the primary pain is ADC workflows, support, or hardware rather than enterprise diversion monitoring, addressing ADC vendor/service issues or choosing a tool tightly coupled to the ADC ecosystem (BD/Omnicell) may be more effective.
KLAS hosts a Sentri7 Drug Diversion user comments page. Access is partially visible but indicates at least some direct customer feedback exists, including both positive selection rationale and operational challenges.
Examples (partial excerpts visible on the KLAS comments page):
Interpretation: KLAS indicates real deployments, but full comment context typically requires KLAS access.
There are a few healthcare IT and pharmacy threads where Sentri7 is mentioned, but detailed, product-specific diversion reviews are sparse.
Examples:
Net: Community chatter exists but is not a rich, structured review dataset for the diversion module.
Wolters Kluwer published a vendor case study describing the product’s lineage from an NIH-backed adaptation project and detailing integration and scale. The case study cites multiple years of historical records, millions of drug transactions, thousands of healthcare professionals, and integration across several distinct systems.
Critical evaluation:
A 2022 paper in the American Journal of Health-System Pharmacy describing ML/advanced analytics for drug diversion detection (using Flowlytics in four health systems) reports very high model performance metrics in the evaluation dataset for accuracy, specificity, and sensitivity.
Critical evaluation:
Wolters Kluwer’s Sentri7® Drug Diversion is a healthcare-focused analytics and case-management solution designed to assist hospitals and health systems in detecting, investigating, documenting, and reporting potential medication diversion (controlled and non-controlled) across the medication lifecycle (purchase → inventory → dispense/admin → waste/return). The product uses AI/ML-based anomaly detection and integrates multiple data sources to reduce manual report building and reconcile data gaps more quickly.
Wolters Kluwer describes the solution as using AI for drug diversion monitoring and states that it synthesizes data from numerous source systems and evaluates dozens of determinants of risk across several distinct data sources. The vendor reports a very high degree of automated reconciliation to support Controlled Substances Act/DEA inspection readiness; this vendor-reported figure should be validated during procurement.